Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Profarma Distribuidora De Produtos Farmaceuticos Debt-to-Equity Related Terms
Profarma Distribuidora De Produtos Farmaceuticos Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profarma Distribuidora De Produtos Farmaceuticos Debt-to-Equity Chart
Profarma Distribuidora De Produtos Farmaceuticos Annual Data
BSP:PFRM3 vs MCK, COR, CAH: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Profarma Distribuidora De Produtos Farmaceuticos's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profarma Distribuidora De Produtos Farmaceuticos Debt-to-Equity vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) has a Debt-to-Equity of 1.32 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Profarma Distribuidora De Produtos Farmaceuticos and its competitors. This is 43% above median its historical median of 0.92. Over the past decade, Profarma Distribuidora De Produtos Farmaceuticos' Debt-to-Equity has ranged from 0.58 to 1.32. According to the industry distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #84 out of 99 companies in the Medical Distribution industry, placing it in the top 84.8%.
Is Profarma Distribuidora De Produtos Farmaceuticos' Debt-to-Equity too high?
Profarma Distribuidora De Produtos Farmaceuticos' current Debt-to-Equity of 1.32 is 43% above median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 1.32. The Medical Distribution industry median Debt-to-Equity is 0.48. Profarma Distribuidora De Produtos Farmaceuticos' value of 1.32 is 175% above this industry median. Based on the distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #84 out of 99 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Profarma Distribuidora De Produtos Farmaceuticos has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Profarma Distribuidora De Produtos Farmaceuticos' Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #84 out of 99 companies for Debt-to-Equity. This places Profarma Distribuidora De Produtos Farmaceuticos in the lower half of its industry. The industry median Debt-to-Equity is 0.48. Profarma Distribuidora De Produtos Farmaceuticos' value of 1.32 is 175% above this benchmark. Historically, Profarma Distribuidora De Produtos Farmaceuticos' own Debt-to-Equity has ranged from 0.58 to 1.32 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 0.48, Profarma Distribuidora De Produtos Farmaceuticos has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profarma Distribuidora De Produtos Farmaceuticos's current Debt-to-Equity of 1.32 is 175% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Profarma Distribuidora De Produtos Farmaceuticos and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profarma Distribuidora De Produtos Farmaceuticos's current Debt-to-Equity is 1.32, which is 43% above median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profarma Distribuidora De Produtos Farmaceuticos stock overvalued right now?
Based on GuruFocus' analysis, Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.49, compared to a current price of R$6.99 — trading 17.7% below its estimated fair value. The current Debt-to-Equity is 1.32, which is 43% above median its 10-year median of 0.92 and 175% above the Medical Distribution industry median of 0.48. Profarma Distribuidora De Produtos Farmaceuticos' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3), the current Debt-to-Equity is 1.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) Overvalued in 2026?
Based on GuruFocus' analysis, Profarma Distribuidora De Produtos Farmaceuticos stock appears to be undervalued.
The current stock price of R$6.99 is trading 17.7% below its estimated GF Value™ of R$8.49.
GuruFocus considers Profarma Distribuidora De Produtos Farmaceuticos to be Modestly Undervalued.
Key valuation signals for BSP:PFRM3:
Debt-to-Equity: 1.32 (43% above median its 10-year median of 0.92)
GF Value™: R$8.49 vs. price of R$6.99 (17.7% below fair value)
Industry Position: 175% above the Medical Distribution median (#84 of 99)
No single metric tells the full story. See the BSP:PFRM3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profarma Distribuidora De Produtos Farmaceuticos SA is a Brazil-based company. It is engaged in wholesale and distribution of pharmaceuticals, cosmetics and similar products, and toiletries. Profarma also holds interests in other companies, regardless of their business sector. The company through its logistics department distributes products in the South, Southeast, Northeast and Center-West regions of Brazil. The firm operates in the pharmaceutical distribution, hospital and specialty, retail segments.
75GF Score
Get the complete analysis for BSP:PFRM3
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PFRM3 has been successfully added to your 
